Alnylam Pharmaceuticals | ALNY - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amgen USD 541M 1000K 2026-06
Arrowhead Research USD 141.14M 564K 2026-06
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.55M 50K 2026-06
Novartis USD 1.91B 60K 2026-03
PTC Therapeutics USD 82.88M 1.41M 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sanofi EUR 1.2B 16.88M 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
Takeda JPY 1.58B 460K 2026-06
Tectonic Therapeutic USD 18.83M 92.19K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 253.3M 900K 2026-06
Xencor USD 74.33M 265K 2026-06